Skip to main content

Dr. Craig H. Moskowitz, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
38
In the NPI registry since
2006
Medicare patients seen, 2024
101

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1988Medical school: Wayne State University School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    FL license ME135617 · NY license 179435

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
101
Services billed
296
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes15888
Established patient office or other outpatient visit, 40-54 minutes7446
Established patient office or other outpatient visit, 20-29 minutes1713
New patient office or other outpatient visit, 60-74 minutes1111

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Acyclovir
Other prescribers in Miami, FL
58
Brukinsa (zanubrutinib)42
Prednisone
Other prescribers in Miami, FL
29
Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim)
Other prescribers in Miami, FL
23
Calquence (acalabrutinib maleate)14
Atovaquone12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 6 companies reported 13 payments worth $16,765 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$9,298
Consulting Fee$7,038
Food and Beverage$429

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jul 2, 2025Takeda Pharmaceuticals U.S.A., Inc.
Jul 2, 2025
Compensation for services other than consulting (speaking, faculty)
ADCETRIS · ONCOLOGY
$5,493
Feb 11, 2025Takeda Pharmaceuticals U.S.A., Inc.
Feb 11, 2025
Compensation for services other than consulting (speaking, faculty)
ADCETRIS · ONCOLOGY
$3,806
Jul 2, 2025Pfizer Inc.
Jul 2, 2025
Consulting Fee
ADCETRIS · ONCOLOGY
$2,160
Jun 24, 2025Pfizer Inc.
Jun 24, 2025
Consulting Fee
ADCETRIS · ONCOLOGY
$2,160
May 29, 2025Incyte Corporation
May 29, 2025
Consulting Fee$2,055
Jul 14, 2025AbbVie Inc.
Jul 14, 2025
Consulting Fee
EPKINLY · ONCOLOGY
$363
Nov 17, 2025Takeda Pharmaceuticals U.S.A., Inc.
Nov 17, 2025
Consulting Fee$300

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $524,611 in research payments for these studies, mostly to the institutions running them.

  • A phase 1 openlabel study to evaluate SGN35C in adults with advanced malignancies
    Pfizer Inc.
  • Pembrolizumab and Site Radiation Therapy for Early Stage Hodgkin Lymphoma
    Merck Sharp & Dohme LLC
  • An openlabel phase 1 study to evaluate the safety of SGN35T in adults with advanced malignancies
    Pfizer Inc.
  • C4811001 study name not available yet
    Pfizer Inc.
  • HD12 a randomized phase iii trial with a pet response adapted design comparing abvd rt with A2VD rt in patients with previously untreated stages iaiia hodgkin lymphoma
    Pfizer Inc.
  • A Phase I/IIa, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an anti-PD-1 and anti-TIM3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical…
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Miami

Sources

NPI registry (CMS NPPES, November 2026; record last updated May 7, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1053402503. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.